Sie sind bereits eingeloggt. Klicken Sie auf 2. tolino select Abo, um fortzufahren.
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei bücher.de, um das eBook-Abo tolino select nutzen zu können.
The book targets new advances in areas of treatment and drug delivery sciences for tuberculosis. It covers advances in drug therapy and drug targeting that focus on innovative trend defining technologies and drug delivery platforms in the understanding of host-pathogens relationship for providing better therapy. A wide variety of novel and nano-formulations using promising technologies are being explored to deliver the drug via different administration routes. This book It addresses the gap between new approaches and old treatment modalities and how they are superior in pharmacological…mehr
The book targets new advances in areas of treatment and drug delivery sciences for tuberculosis. It covers advances in drug therapy and drug targeting that focus on innovative trend defining technologies and drug delivery platforms in the understanding of host-pathogens relationship for providing better therapy. A wide variety of novel and nano-formulations using promising technologies are being explored to deliver the drug via different administration routes. This book It addresses the gap between new approaches and old treatment modalities and how they are superior in pharmacological performance when tested in in-vitro and in-vivo. Audience from wide range group like from researchers to regulatory bodies can benefit from the compiled information to find out patient needs and current research advances in the field of tuberculosis research. .
Dr. Ranjita Shegokar holds a Ph.D. degree in Pharmaceutical Technology from the SNDT University, India, and has been a postdoctoral researcher in the Department of Pharmaceutics, Biopharmaceutics and NutriCosmetics at the Free University of Berlin, Germany. Since last several years she is working with various multinational pharmaceutical companies at technical/R&D leadership roles. Currently, she serves as a Chief Scientific Officer, CapnoPharm GmbH, Germany. She has authored several research articles, book chapters, and presented her research in many national/international conferences. She has filed multiple patent applications in the area of drug delivery and active targeting. Besides that, she edited many trending books on nanoparticles and their aspects. For her research, she received many prestigious national and international awards, among them the recent one is German Innovation Award 2022. Her areas of interest include polymeric nanoparticles, nanocrystals, lipid nanoparticles (SLNs/NLCs), nanoemulsions for targeting various diseases and the role of excipients in developing the same.
Dr. Yashwant Pathak completed his Ph.D. in Pharmaceutical Technology from India and EMBA and MS Conflict Management from Sullivan University, USA. He is Associate Dean for Faculty Affairs College of Pharmacy, University of South Florida. Tampa, Florida. With extensive experience in academia and industry, he has over 150 research publications, abstracts, chapters and reviews, 7 books in Nanotechnology and drug delivery systems, 6 in Nutraceuticals and several books in cultural studies. His areas of research include drug delivery systems, nanotechnology applications for pharmaceutical and Nutraceuticals. He has traveled extensively over 80 countries to network scientific experts and is actively involved with many Pharmacy colleges in different countries.
Inhaltsangabe
Global health and Tuberculosis past, present and Future.- Tuberculosis: cellular understanding of disease.-Metal nanoparticles in TB.- TB: current treatment options.- Polymeric nanoparticles in TB.- Solid lipid nanoparticles in TB.- Dendrimers in TB.- Liposomes in TB.- Micro, nano emulsions in TB.- Nano suspension in TB.- Alginate, gelatin nanoparticles in TB.- Niosome in TB.- Surface modified drug delivery systems in TB.- Clinical trials in TB.- Herbal platforms in TB.
Global health and Tuberculosis past, present and Future.- Tuberculosis: cellular understanding of disease.-Metal nanoparticles in TB.- TB: current treatment options.- Polymeric nanoparticles in TB.- Solid lipid nanoparticles in TB.- Dendrimers in TB.- Liposomes in TB.- Micro, nano emulsions in TB.- Nano suspension in TB.- Alginate, gelatin nanoparticles in TB.- Niosome in TB.- Surface modified drug delivery systems in TB.- Clinical trials in TB.- Herbal platforms in TB.
Global health and Tuberculosis past, present and Future.- Tuberculosis: cellular understanding of disease.-Metal nanoparticles in TB.- TB: current treatment options.- Polymeric nanoparticles in TB.- Solid lipid nanoparticles in TB.- Dendrimers in TB.- Liposomes in TB.- Micro, nano emulsions in TB.- Nano suspension in TB.- Alginate, gelatin nanoparticles in TB.- Niosome in TB.- Surface modified drug delivery systems in TB.- Clinical trials in TB.- Herbal platforms in TB.
Global health and Tuberculosis past, present and Future.- Tuberculosis: cellular understanding of disease.-Metal nanoparticles in TB.- TB: current treatment options.- Polymeric nanoparticles in TB.- Solid lipid nanoparticles in TB.- Dendrimers in TB.- Liposomes in TB.- Micro, nano emulsions in TB.- Nano suspension in TB.- Alginate, gelatin nanoparticles in TB.- Niosome in TB.- Surface modified drug delivery systems in TB.- Clinical trials in TB.- Herbal platforms in TB.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497